Methotrexate Teva

Methotrexate, the active ingredient in Methotrexate Teva, is an antimetabolite (folate antagonist) presented as a sterile injectable formulation for epidural, intrabursal and intracoronary use. It treats rheumatoid arthritis, psoriasis, acute lymphoblastic leukemia, non‑Hodgkin lymphoma and gestational trophoblastic disease in appropriate patients. It is indicated for use in adult and pediatric populations as determined by the prescribing clinician.

GNH USA supplies Methotrexate Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, with a focus on quality assurance, regulatory compliance and reliable global logistics.

Methotrexate is an antimetabolite that interferes with folate metabolism, used in several autoimmune and oncologic conditions.

- Rheumatoid arthritis: reduces disease activity and joint inflammation. - Psoriasis: slows skin cell proliferation and improves lesions. - Acute lymphoblastic leukemia: inhibits malignant cell growth. - Non‑Hodgkin lymphoma: induces tumor cell apoptosis. - Gestational trophoblastic disease: promotes resolution of abnormal trophoblastic tissue.

Methotrexate may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea or vomiting. - Fatigue or malaise. - Oral ulcers or mucositis. - Mild elevation of liver enzymes. - Decreased white blood cell count. - Mild rash.

Serious or Rare Side Effects: - Severe liver toxicity or hepatitis. - Pulmonary fibrosis or interstitial pneumonitis. - Significant bone marrow suppression leading to anemia, neutropenia or thrombocytopenia. - Acute renal failure. - Life‑threatening infections. - Anaphylactic or severe allergic reactions.

Methotrexate requires careful monitoring and specific safety measures before and during therapy.

- Pregnancy: contraindicated (Category X) – avoid use in pregnant or trying-to-conceive patients. - Renal function: assess baseline creatinine and adjust dose in impairment. - Hepatic function: monitor liver enzymes regularly; avoid in severe liver disease. - Hematologic monitoring: perform complete blood counts to detect bone‑marrow suppression. - Drug interactions: review concomitant medications for potential toxicity. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Methotrexate interacts with several drug classes; some combinations must be avoided while others require close observation.

Major Interactions (Avoid): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase methotrexate toxicity. - Penicillins (e.g., ampicillin): reduce renal clearance, raising serum levels. - Live vaccines: heightened risk of infection due to immunosuppression.

Moderate Interactions (Monitor Closely): - Sulfonamides: additive bone‑marrow suppression. - Proton pump inhibitors: may affect methotrexate absorption. - Azathioprine or other immunosuppressants: combined effect on immune function. - Trimethoprim‑sulfamethoxazole: increased risk of hematologic toxicity. - Vitamin supplements containing folic acid: may diminish therapeutic effect.